Manufacturer : Pharmacom
Raw Material : Drostanolone Propionate 100 mg/ml Drostanolone Enanthate 200 mg/ml
Product Pack : 300 mg/ml
Shipping Line : Asia Line
PHARMAMIX M300 is a blend of two drostanolone esters: propionate and enanthate. It is designed to provide a fast yet extended release of drostanolone. This blend is perfect for long cycles to ensure high quality lean muscle bulk and dense look without excess subcutaneous water retention typical found with long esters. It combines well with testosterone and trenbolone blends (PHARMASUST 300, 500, PHARMA 3TREN) and long testosterone and trenbolone esters (PHARMATEST E300, E500, C250; PHARMATREN E200, H100). A similar stack is implemented in our last development – PHARMAMIX 6, which has already earned a total sales success similarly to PHARMAMIX 2.
Drostanolone was first described in 1959; developed by Syntex and entered the market more than a decade later, in 1970, under the trade name Masteron.
Drostanolone is an injectable anabolic steroid, a derivative of dihydrotestosterone (DHT). It is described in medical literature as a strong anabolic with anti-estrogenic traits. The FDA approved drostanolone for the treatment of inoperable breast cancer in climacteric women, as was the case in many other parts of the worlds.
Biologically, Masteron acts like DHT, as it is a derivative of the latter. Without question, the effects of Masteron will be displayed in the most efficient way during a cutting cycle. However, for the effects to be truly appreciated the individual will need to be extremely lean. Drostanolone does not cause water retention and has a moderate diuretic effect similarly to stanozolol; this allows improving muscles density, relief and definition. Drostanolone allows achievement of the best muscle condition; it is possible thanks largely to the lipolytic effect of the compound. As practice shows, a drostanolone cycle can reduce body fat by 5-7%. Drostanolone is recommended for track and field athletes and bodybuilders who want to stay within their particular weight class.
As a bulking agent, the effects of Masteron will prove to be rather weak. It is possible the hormone could provide gains in mass similar to Primobolan (which wouldn't be that strong either) if the total dose was sufficiently high. However, the relative gain in size will be moderate with many anabolic steroids being far more suited for this period of steroidal supplementation. Masteron does not aromatize and is not estrogenic; in fact, it shows anti-estrogenic traits in the body and binds to aromatase instead of other substrates. This is why it has been effective in the treatment of breast cancer.
To summarize, drostanolone acts very similar to stanozolol, however it does not have side effects typical for Winstrol, namely it does not increase tendon brittleness, does not dry out the joint fluid and does not have such an adverse effect on blood cholesterol as stanozolol does. If one were to choose between drostanolone and stanozolol for a cutting cycle, drostanolone would be a more reasonable and safer option!